NeuroDerm Announces Streamlined U.S. Development Plan on ND0612H and ND0612L for the Treatment of PD

(November 11, 2015) – NeuroDerm announced that it has modified its U.S. development plan for ND0612H and ND0612L, the company’s continuous, subcutaneously delivered levodopa/carbidopa product candidates for the treatment of Parkinson’s disease. Based on FDA input, NeuroDerm is not required to conduct its largest Phase III pivotal trial of 360 patients. Read more…